Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Viral immunosuppression: disabling the guards.

Marco Colonna1

  • 1Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110, USA. mcolonna@pathology.wustl.edu

The Journal of Clinical Investigation
|March 3, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy.

Nature cancer·2025
Same author

Myofibroblastic CAFs arising from bone-resident osteoblast precursors retain an osteolineage signature and support breast cancer progression via Osterix-mediated signaling.

bioRxiv : the preprint server for biology·2025
Same author

SLC7A8 is essential for metabolic fitness and function of Th2 cells.

The Journal of experimental medicine·2025
Same author

Membrane IL-18 identifies a human macrophage subset with distinct proteomic and functional traits.

Oncoimmunology·2025
Same author

Dual threat: VSIG4⁺ macrophages use IL-11 and VSIG4 to silence T cells.

Developmental cell·2025
Same author

Fate mapping of peripherally-derived macrophages after traumatic brain injury in mice reveals a long-lasting population with a distinct transcriptomic signature.

Nature communications·2025
Same journal

Julie Zikherman receives the ASCI/Marian W. Ropes, MD, Award.

The Journal of clinical investigation·2026
Same journal

Targeted degradation of MDM2 overcomes feedback regulation of p53 signaling in Merkel cell carcinoma models.

The Journal of clinical investigation·2026
Same journal

SGLT2 inhibitors enhance ketogenesis by acting as allosteric activators of the mitochondrial enzyme HMGCS2.

The Journal of clinical investigation·2026
Same journal

MDM2 degraders for Merkel cell carcinoma: round peg in a round hole.

The Journal of clinical investigation·2026
Same journal

Ammonia in the crosshairs: microbial targets for metabolic dysfunction-associated steatohepatitis prevention.

The Journal of clinical investigation·2026
Same journal

Molecular mechanisms regulating cGAS/STING activation in health and disease.

The Journal of clinical investigation·2026
See all related articles

This study shows how a lymphocytic choriomeningitis virus (LCMV) strain suppresses immune cells called dendritic cells (DCs). This viral immune evasion offers new therapeutic strategies for chronic infections.

Area of Science:

  • Virology
  • Immunology
  • Infectious Diseases

Background:

  • Viruses employ diverse strategies to evade host immune responses.
  • Dendritic cells (DCs) are crucial for initiating adaptive immunity.
  • Understanding viral immune evasion is key to developing effective therapies.

Purpose of the Study:

  • To investigate the mechanisms by which a lymphocytic choriomeningitis virus (LCMV) strain suppresses immune responses.
  • To elucidate the role of DCs in LCMV-induced immunosuppression.
  • To identify potential therapeutic targets for chronic viral infections.

Main Methods:

  • Infection of host models with a specific LCMV strain.
  • Analysis of DC development and activation markers.
  • Assessment of type I Interferon (IFN) signaling pathways.

Related Experiment Videos

Main Results:

  • LCMV strain identified that targets both DC development and activation.
  • Type I IFN, induced by LCMV, paradoxically inhibits DC development.
  • Viral suppression of DCs effectively hinders immune response initiation.

Conclusions:

  • LCMV utilizes a novel mechanism to suppress host immunity by targeting DCs.
  • Type I IFN plays an unexpected dual role in LCMV infection, contributing to immunosuppression.
  • These findings open new avenues for treating chronic infections characterized by immune suppression.